round button
Leave a message

中東およびアフリカのトランスフェクション試薬および機器市場 – 2030 年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカのトランスフェクション試薬および機器市場 – 2030 年までの業界動向と予測

  • Medical Devices
  • Published Report
  • Mar 2023
  • MEA
  • 350 ページ
  • テーブル数: 45
  • 図の数: 57

中東およびアフリカのトランスフェクション試薬および機器市場、製品別(試薬、キット、機器)、段階別(研究、前臨床、臨床段階、および商業)、タイプ別(一過性トランスフェクション試薬および機器、安定トランスフェクション試薬および機器)、方法別(非ウイルス法およびウイルス法)、分子の種類別(プラスミド DNA、低分子干渉 RNA(siRNA)、タンパク質、DNA オリゴヌクレオチド、リボ核タンパク質複合体(RNP)、およびその他)、生物別(哺乳類細胞、植物、真菌、ウイルス、および細菌)、用途別(インビトロ用途、インビボ用途、バイオプロダクション、およびその他)、エンドユーザー別(バイオ医薬品、CRO、(CMO/CDMO)、学術機関、病院、臨床検査室、およびその他)、流通チャネル別(直接入札、小売販売、およびその他)、2030 年までの業界動向および予測

中東およびアフリカのトランスフェクション試薬および機器市場

中東およびアフリカのトランスフェクション試薬および機器市場の分析と洞察

トランスフェクションでは、ウイルスおよび非ウイルスの方法により真核細胞に核酸を導入します。トランスフェクション法は、負に帯電した膜を移動させるという課題を克服できます。リン酸カルシウムやジエチルアミノエチル (DEAE) デキストラン、またはカチオン性脂質ベースの試薬などの化学物質は、DNA の外側のコートと反応します。これにより、全体の負電荷が中和され、分子に正の電荷が付与されるため、DNA の送達が可能になります。エレクトロポレーションなどの物理的方法では、電圧を印加することで細胞膜に微細な孔が作られ、DNA が細胞質に直接入り込むことができます。DEAE デキストランは一過性のトランスフェクションに使用されますが、リポフェクションでは安定したトランスフェクションが達成できるため、長期的なタンパク質発現に使用できます。リン酸カルシウムを介したトランスフェクションも、安定したトランスフェクションに使用できます。ウイルスによるトランスフェクション法は効率が高く、医薬品開発のいくつかの段階で使用されます。

中東およびアフリカのトランスフェクション試薬および機器市場

中東およびアフリカのトランスフェクション試薬および機器市場

トランスフェクション法は、農作物の保護や収穫量の増加、風味や香りを高める合成生物学製品の製造、単細胞タンパク質の強化など、農業に関わるさまざまな用途に使用されています。トランスフェクションの需要は先進国と発展途上国の両方で増加しており、その背景には慢性疾患の発生の増加があります。トランスフェクション市場は、キメラ遺伝子の需要の増加とタンパク質製造におけるバイオ医薬品の利用により成長しています。市場は、新興市場の探索、市場プレーヤーによる戦略的イニシアチブ、および政府支援の増加により、予測期間中に成長するでしょう。

The high cost of instruments, selective effectiveness of transfection reagent and cell damage induced by the transfection methods are expected to restrain the Middle East and Africa transfection reagent and equipment market growth.

The market is growing due to several strategic initiatives adopted by market players involving acquisition, collaboration, and partnership.

Data Bridge Market Research analyzes that the Middle East and Africa transfection reagent and equipment market is expected to reach the value of USD 36,134.85 thousand by 2030, at a CAGR of 7.0% during the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2016)

Quantitative Units

Revenue in Thousand, Volumes in Units, Pricing in USD

Segments Covered

By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bioproduction and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).

Countries Covered

South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of the Middle East and Africa.

Market Players Covered

Some of the major players operating in this market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation), Avanti Polar Lipids (A Subsidiary of  Croda International Plc),  PerkinElmer chemagen Technologie GmbH (A Subsidiary of  PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (A Subsidiary of Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc., and Twist Bioscience, among others.

Market Definition

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in the field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

Middle East and Africa Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the Middle East and Africa transfection Reagent and equipment market growth.

  • DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the Middle East and Africa transfection Reagent and equipment market growth.

Restraint

  • CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the Middle East and Africa transfection Reagent and equipment market growth.

Opportunity

  • EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the Middle East and Africa transfection Reagent and equipment market.

Challenge

  • LONG APPROVAL PROCEDURE

The long approval procedure for transfection Reagent and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the Middle East and Africa transfection Reagent and equipment market growth.

Recent Developments

  • In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
  • In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

Middle East and Africa Transfection Reagent and Equipment Market Scope

Middle East and Africa transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

  • INSTRUMENTS
  • REAGENT & KITS

On the basis of products, the Middle East and Africa transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

  • RESEARCH
  • PRECLINICAL
  • CLINICAL PHASES
  • COMMERCIAL

On the basis of stage, the Middle East and Africa transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

  • TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
  • STABLE TRANSFECTION REAGENT AND EQUIPMENT

タイプに基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、一過性トランスフェクション試薬および機器と、安定トランスフェクション試薬および機器に分類されます。

方法

  • 非ウイルス性の方法
  • ウイルスによる方法

方法に基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、非ウイルス法とウイルス法に分類されます。

分子の種類

  • プラスミドDNA
  • DNAオリゴヌクレオチド
  • 低分子干渉RNA(SIRNA)
  • タンパク質
  • リボ核タンパク質複合体(RNPS)
  • その他

分子の種類に基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、プラスミド DNA、DNA オリゴヌクレオチド、低分子干渉 RNA (siRNA)、タンパク質、リボ核タンパク質複合体 (RNP) などに分類されます。

生物

  • 細菌
  • 哺乳類細胞
  • 菌類
  • 植物
  • ウイルス

生物に基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、細菌、哺乳類細胞、真菌、植物、ウイルスに分類されます。

応用

  • タイプ別
    • インビトロアプリケーション
    • 生体内応用
    • バイオプロダクション
    • その他
  • 業界別
    • 農業
    • 合成生物学
    • その他

用途に基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、タイプ別に in vitro 用途、in vivo 用途、バイオプロダクション、その他に分類され、業界別には農業、合成生物学、その他に分類されています。

エンドユーザー

  • バイオ医薬品
  • クロス
  • CMOS/CDMOS
  • 学術
  • 病院
  • 臨床検査室
  • その他

エンドユーザーに基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、バイオ医薬品、CRO、CMO/CDMO、学術機関、病院、臨床検査室、その他に分類されます。

流通チャネル

  • 直接入札
  • 小売販売
  • その他

流通チャネルに基づいて、中東およびアフリカのトランスフェクション試薬および機器市場は、直接入札、小売販売、その他に分類されます。

中東およびアフリカのトランスフェクション試薬および機器市場地域分析/洞察

中東およびアフリカのトランスフェクション試薬および機器市場は、地理、製品、段階、方法、タイプ、分子の種類、用途、エンドユーザー、生物、流通チャネルなど、多くの注目すべきセグメントに分類されています。

この市場レポートで取り上げられている国は、南アフリカ、サウジアラビア、UAE、イスラエル、エジプト、その他の中東およびアフリカ諸国です。

南アフリカは、希少疾患や慢性疾患の増加により、中東およびアフリカ地域で優位に立っています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、中東およびアフリカのブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、および販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。

競争環境と中東およびアフリカのトランスフェクション試薬および機器市場シェア分析

中東およびアフリカのトランスフェクション試薬および機器市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、製品タイプのライフライン曲線が含まれます。上記のデータ ポイントは、中東およびアフリカのトランスフェクション試薬および機器市場への会社の重点にのみ関連しています。

この市場で活動している主な企業としては、Mirus Bio LLC、Promega Corporation、Polyplus Transfection、Bio-Rad Laboratories, Inc.、Merck KGaA、Lonza、MaxCyte, Inc.、Altogen Biosystems、SBS Genetech、FUJIFILM Irvine Scientific(FUJIFILM Holdings Corporation の子会社)、Avanti Polar Lipids(Croda International Plc の子会社)、PerkinElmer chemagen Technologie GmbH(PerkinElmer Inc. の子会社)、Cytiva、Geno Technology Inc.、USA、R&D Systems, Inc.、Takara Bio Inc.、Thermofisher Scientific Inc.、Roche Molecular Systems, Inc.(F. Hoffmann-La Roche Ltd の子会社)、QIAGEN、OriGene Technologies, Inc.、Applied Biological Materials Inc.(abm)、Beckman Coulter, Inc.(ダナハー社、アミリス社、コデキシス社、オートラス社、シグナジェン・ラボラトリーズ社、インポッシブル・フーズ社、ジェンランティス社、ギンゴ・バイオワークス社、ヴァーヴ・セラピューティクス社、コナジェン社、ポセイダ・セラピューティクス社、ツイスト・バイオサイエンス社など。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS:

6 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS

6.1 EUROPEAN UNION REGULATORY SCENARIO

6.2 U.S. REGULATORY SCENARIO

6.3 JAPAN REGULATORY SCENARIO

6.4 CHINA REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES

7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

7.1.3 GROWING DEMAND FOR CHIMERIC GENES

7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH

7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS

7.2 RESTRAINTS

7.2.1 HIGH COST OF TRANSFECTION PRODUCTS

7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS

7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

7.3 OPPORTUNITIES

7.3.1 EXPLORATION OF EMERGING MARKET

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 SURGING LEVEL OF INVESTMENT

7.4 CHALLENGES

7.4.1 LONG APPROVAL PROCEDURE

7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION

7.4.3 LACK OF TRAINED PROFESSIONALS

8 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 REAGENTS & KITS

8.3 INSTRUMENTS

9 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE

9.1 OVERVIEW

9.2 RESEARCH

9.3 PRECLINICAL

9.4 CLINICAL PHASES

9.5 COMMERCIAL

10 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT

10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT

11 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS

11.1 OVERVIEW

11.2 NON-VIRAL METHODS

11.3 VIRAL METHODS

12 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE

12.1 OVERVIEW

12.2 PLASMID DNA

12.3 SMALL INTERFERING RNA (SIRNA)

12.4 PROTEINS

12.5 DNA OLIGONUCLEOTIDES

12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)

12.7 OTHERS

13 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM

13.1 OVERVIEW

13.2 MAMMALIAN CELLS

13.3 PLANTS

13.4 FUNGI

13.5 VIRUS

13.6 BACTERIA

14 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 IN VITRO APPLICATION

14.2.1 IN VIVO APPLICATION

14.2.2 BIOPRODUCTION

14.2.3 OTHERS

14.2.4 SYNTHETIC BIOLOGY

14.2.5 AGRICULTURE

14.2.6 OTHERS

15 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 BIOPHARMA

15.3 CROS

15.4 CMOS/CDMOS

15.5 ACADEMIA

15.6 HOSPITALS

15.7 CLINICAL LABS

15.8 OTHERS

16 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.4 OTHERS

17 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION

17.1 MIDDLE EAST AND AFRICA

17.1.1 SOUTH AFRICA

17.1.2 SAUDI ARABIA

17.1.3 U.A.E.

17.1.4 EGYPT

17.1.5 ISRAEL

17.1.6 REST OF MIDDLE EAST AND AFRICA

18 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 THERMO FISHER SCIENTIFIC INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 PROMEGA CORPORATION

20.3.1 COMPANY SNAPSHOT

20.3.2 COMPANY SHARE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENT

20.4 TAKARA BIO INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 BIO-RAD LABORATORIES, INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANANLYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 ALTOGEN BIOSYSTEMS

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM)

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 CYTIVA

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENT

20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANANLYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENT

20.12 GENLANTIS INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 GENO TECHNOLOGY INC., USA

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 GINKGO BIOWORKS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENTS

20.15 LONZA

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANANLYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 MAXCYTE, INC.

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 MERCK KGAA

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENT

20.18 MIRUS BIO LLC.

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENT

20.19 ORIGENE TECHNOLOGIES, INC.

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENT

20.2 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)

20.20.1 COMPANY SNAPSHOT

20.20.2 REVENUE ANALYSIS

20.20.3 PRODUCT PORTFOLIO

20.20.4 RECENT DEVELOPMENT

20.21 POLYPLUS TRANSFECTION

20.21.1 COMPANY SNAPSHOT

20.21.2 PRODUCT PORTFOLIO

20.21.3 RECENT DEVELOPMENT

20.22 R&D SYSTEMS, INC.

20.22.1 COMPANY SNAPSHOT

20.22.2 PRODUCT PORTFOLIO

20.22.3 RECENT DEVELOPMENT

20.23 SBS GENETECH

20.23.1 COMPANY SNAPSHOT

20.23.2 PRODUCT PORTFOLIO

20.23.3 RECENT DEVELOPMENT

20.24 SIGNAGEN LABORATORIES

20.24.1 COMPANY SNAPSHOT

20.24.2 PRODUCT PORTFOLIO

20.24.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

表のリスト

TABLE 1 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND)

TABLE 2 MIDDLE EAST & AFRICA REAGENT AND KITS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE, 2021-2030 (USD THOUSAND)

TABLE 5 MIDDLE EAST & AFRICA RESEARCH IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 MIDDLE EAST & AFRICA PRECLINICAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 7 MIDDLE EAST & AFRICA CLINICAL PHASES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 MIDDLE EAST & AFRICA COMMERCIAL IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 MIDDLE EAST & AFRICA STABLE TRANSFECTION REAGENTS AND EQUIPMENT IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, BY METHODS, 2021-2030 (USD THOUSAND)

TABLE 13 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 14 MIDDLE EAST & AFRICA VIRAL METHODS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 15 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE, 2021-2030 (USD THOUSAND)

TABLE 16 MIDDLE EAST & AFRICA PLASMID DNA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 MIDDLE EAST & AFRICA SMALL INTERFERING RNA (SIRNA) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 MIDDLE EAST & AFRICA PROTEINS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 19 MIDDLE EAST & AFRICA DNA OLIGONUCLEOTIDES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 MIDDLE EAST & AFRICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 MIDDLE EAST & AFRICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM, 2021-2030 (USD THOUSAND)

TABLE 23 MIDDLE EAST & AFRICA MAMMALIAN CELLS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 MIDDLE EAST & AFRICA PLANTS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 MIDDLE EAST & AFRICA FUNGI IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 MIDDLE EAST & AFRICA VIRUS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 MIDDLE EAST & AFRICA BACTERIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET , BY APPLICATION, 2021-2030 (USD THOUSAND)

TABLE 29 MIDDLE EAST & AFRICA IN VITRO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 MIDDLE EAST & AFRICA IN VIVO APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 MIDDLE EAST & AFRICA BIOPRODUCTION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 MIDDLE EAST & AFRICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 MIDDLE EAST & AFRICA APPLICATION IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY INDUSTRY, 2021-2030 (USD THOUSAND)

TABLE 34 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 35 MIDDLE EAST & AFRICA BIOPHARMA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 MIDDLE EAST & AFRICA CROS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 MIDDLE EAST & AFRICA CMOS/CDMOS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 MIDDLE EAST & AFRICA ACADEMIA IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 MIDDLE EAST & AFRICA HOSPITALS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 MIDDLE EAST & AFRICA CLINICAL LABS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 MIDDLE EAST & AFRICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 43 MIDDLE EAST & AFRICA DIRECT TENDER IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 44 MIDDLE EAST & AFRICA RETAIL SALES IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 MIDDLE EAST & AFRICA OTHERS IN TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST & AFRICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2030

FIGURE 13 THE TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET IN 2022 & 2030

FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET

FIGURE 16 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023

FIGURE 17 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, 2023-2030 (USD THOUSAND)

FIGURE 18 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, CAGR (2023-2030)

FIGURE 19 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 20 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023

FIGURE 21 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, 2023-2030 (USD THOUSAND)

FIGURE 22 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 23 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY STAGE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023

FIGURE 25 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 26 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 27 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 28 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2022

FIGURE 29 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, 2023-2030 (USD THOUSAND)

FIGURE 30 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, CAGR (2023-2030)

FIGURE 31 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: BY METHODS, LIFELINE CURVE

FIGURE 32 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2022

FIGURE 33 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, 2023-2030 (USD THOUSAND)

FIGURE 34 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, CAGR (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY TYPES OF MOLECULE, LIFELINE CURVE

FIGURE 36 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2022

FIGURE 37 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, 2023-2030 (USD THOUSAND)

FIGURE 38 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, CAGR (2023-2030)

FIGURE 39 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY ORGANISM, LIFELINE CURVE

FIGURE 40 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2022

FIGURE 41 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, 2023-2030 (USD THOUSAND)

FIGURE 42 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, CAGR (2023-2030)

FIGURE 43 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET BY APPLICATION, LIFELINE CURVE

FIGURE 44 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY END USER, 2022

FIGURE 45 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 46 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, CAGR (2023-2030)

FIGURE 47 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 48 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 49 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 50 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 51 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 MIDDLE EAST AND AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: SNAPSHOT (2022)

FIGURE 53 MIDDLE EAST AND AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022)

FIGURE 54 MIDDLE EAST AND AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 55 MIDDLE EAST AND AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 56 MIDDLE EAST AND AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET: BY PRODUCTS (2023-2030)

FIGURE 57 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa Transfection Reagent and Equipment Market is projected to grow at a CAGR of 7.0% during the forecast period by 2030.
The future market value of the Middle East and Africa Transfection Reagent and Equipment Market is expected to reach USD 36,134.85 thousand by 2030.
The major players in the Middle East and Africa Transfection Reagent and Equipment Market are Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific, etc.
The countries covered in the Middle East and Africa Transfection Reagent and Equipment Market are South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of the Middle East and Africa.
a